Articles tagged with Pancreatic Cancer
Researchers identify SRSF1 as a key player in promoting pancreatitis and pancreatic cancer growth. High levels of SRSF1 are associated with worse patient outcomes, highlighting its potential as a target for new therapies.
Jeong Min Lee, KSR President and professor at Seoul National University Hospital, is honored with ARRS membership. He has published over 470 scientific articles and serves on the editorial board of several publications.
Researchers at UC Irvine have identified key themes in the biology of pancreatic cancer that can serve as hallmarks for therapy. These themes include genomic alterations, metabolism, and immunotherapy, which can be combined to improve treatment outcomes.
Researchers have developed an implantable nanofluidic device that delivers CD40 monoclonal antibodies to shrink pancreatic tumors, reducing treatment dosage by fourfold. The device's long-term controlled release avoids systemic side effects, offering a promising alternative for cancer patients.
Researchers analyzed 30 healthy pancreata from diverse donors and found PanIN lesions in 18 cases, which had distinct microenvironments compared to normal pancreatic tissue. The study suggests that PanINs may already possess features of malignant cells and challenges the long-held assumption that they always progress to cancer.
The University of Texas at El Paso will study the role of obesity and inflammation in pancreatic cancer development, a disease with high mortality rates. The grant aims to develop targeted treatments and preventives, potentially transforming understanding of pancreatic cancer.
A study published in the journal Cancer found that long-term pancreatic cancer survivors have a robust immune response and enriched gut microbiome species, including Faecalibacterium prausnitzii. The research suggests that these bacterial species may promote immune response to pancreas cancer.
A new study of over 200 people with premature aging syndromes caused by abnormally short telomeres suggests that chromosomal instability may not be the reason for increased cancer risk. Instead, immune system cells that age and die prematurely may play a role in cancer predisposition.
Cancer cells have been found to employ a strategy to evade the immune system's killer T cells by interacting with myeloid cells and suppressing type 1 interferon production. This natural pathway is crucial for recruiting killer T cells to combat cancer spread. Researchers hope to develop new therapeutic approaches, such as forcing tumo...
Researchers have found that valosin-containing protein (VCP) is essential for KRAS-mutant pancreatic ductal adenocarcinoma cell growth and survival. Inhibiting VCP, combined with autophagy inhibition, enhances efficacy in preclinical studies.
Sylvester researchers have identified a signaling circuit that instigates immunosuppression and tumor-promoting inflammation in the pancreatic tumor microenvironment, driving treatment resistance. Immature neutrophils are found to play a critical role in this process.
A Duke University research team has identified a set of biomarkers that could help distinguish between cysts on the pancreas that are likely to develop into cancer and those that will remain benign. The findings have significant implications for preventing the development of pancreatic cancer, which is on the rise and is notorious for ...
A new radiotracer successfully detected 100% of primary tumors across multiple cancer types, outperforming the current standard. It also showed promise in detecting lymph node and distant metastases, offering a promising alternative for diagnosis and treatment.
Researchers at Karolinska Institutet discovered an immune cell in women with pancreatic cancer that blocks the immune response, leading to poor survival. The study identifies a specific protein FPR2 as a potential therapeutic target for immunotherapy in women.
Researchers at Garvan Institute of Medical Research found that introducing bacteria to a tumor's microenvironment triggers an immune response, activating neutrophils to destroy tumors in animal models. This breakthrough therapy targets neutrophils to improve cancer treatment outcomes.
Researchers at City University of Hong Kong identified lysyl hydroxylase 1 (LH1) as a key factor in promoting confined migration of liver and pancreatic cancer cells. The study found that LH1 promotes metastasis by stabilizing Septin2, which enhances the actin network.
Lung cancer death rates are projected to decrease overall in the EU and UK in 2023, however, a concerning trend is observed among women in France, Italy, and Spain. Meanwhile, pancreatic cancer death rates are forecasted to rise among women due to continued smoking habits.
The use of AI is improving diagnostic accuracy for digestive cancers, but challenges in data sharing and standardization hinder its widespread application. Researchers surveyed recent applications of AI to these deadly cancers, finding that AI can automate complex processes and detect patterns not visible to humans.
Researchers at VCU Massey Cancer Center found that simultaneous activation of Prdm16 and Smad4 proteins slows down pancreatic cancer progression. The study suggests a novel therapeutic approach to tackle this deadly disease.
A new study found that chemotherapy alters the immune cell landscape in pancreatic cancer, reducing checkpoint molecules and increasing tumor growth. The research suggests that this may lead to resistance to subsequent immunotherapy, highlighting the need for further study on combining chemotherapy with immunotherapy.
A recent study confirms that pancreatic cancer rates are rising faster in women than men, particularly among younger women and Black women. The rate of pancreatic cancer among women under the age of 55 increased by 2.4% compared to men of the same age, highlighting a significant disparity in mortality rates between the sexes.
Researchers explore CEACAM1, CEACAM5, and CEACAM6's pathological significance in cancer biology and immunology. The review highlights their interactions with pathogens and potential avenues for cancer therapy.
The NCI is funding a $587,000 research grant to improve KRAS treatment resistance in pancreatic cancer. Dr. Andrew Waters aims to develop personalized medicine approaches by studying unique resistance mechanisms.
Researchers detected high levels of hydrogen peroxide in pancreatic cancer cells, which makes it a critical target for cancer treatment and research. The study also showed that cancer-promoting mutations lead to suppressed genetic expression of enzymes breaking down hydrogen peroxide.
Researchers found that primary cancer tumors have a sluggish conversion of nutrients to usable cellular energy, conserving energy for growth and metastasis. The discovery has vast implications for anti-cancer strategies, directing attention to slow energy metabolism.
Researchers analyzed tumor microenvironment of pancreatic cancer, revealing two major defects that inhibit immune response. The study suggests a new approach using anti-CD137 agonist antibody treatment in combination with anti-PD-1 immunotherapy to activate T cells.
A Phase 3 clinical trial has shown that a four-drug chemotherapy regimen significantly increases overall survival and progression-free survival in patients with stage 4 pancreatic ductal adenocarcinoma. The study's results suggest that this more aggressive treatment approach may be considered for eligible patients.
Researchers at MUSC Hollings Cancer Center discovered the cellular origin of normal pancreatic fibroblasts and cancer-associated fibroblasts, which play a key role in tumor progression. The findings suggest that targeting cancer-associated fibroblasts holds exciting potential for therapeutic benefits.
Researchers at UC San Diego describe how pancreatic cancer stem cells leverage SMARCD3, a protein that normally suppresses tumors, to boost resistance to treatments and drive growth. Deleting SMARCD3 reduces tumor growth and improves survival rates.
Researchers discovered a molecular pathway critical to the initiation of pancreatic tumors, which can contribute to disease resistance and metastasis. Targeting this pathway could limit tumor progression, relapse, and spread by disrupting the interaction between cancer cells and their microenvironment.
Scientists have found a way to break down the resistance of mice with neuroendocrine pancreatic cancer to checkpoint blockade immunotherapy. A new drug combination, PD1-IL2v and anti-PD-L1, enhances anti-tumor immunity by stimulating specific T cells and reprogramming macrophages, leading to increased survival rates in tumor-bearing mice.
Researchers are working to understand the events contributing to pancreatic cancer development by studying gene abnormalities and their effects on the disease. Dr. Krushna Patra's lab is focused on understanding how genetic mutations like GNAS contribute to pancreatic cancer growth.
Researchers at Cima Universidad de Navarra identified LAMC2 as a key gene in pancreatic cancer development. Inhibiting this gene, combined with existing drugs, increases antitumor effect in 3D models.
Researchers at MD Anderson Cancer Center have discovered a novel triple immunotherapy combination targeting checkpoints in T cells and myeloid suppressor cells, improving anti-tumor responses and survival rates in preclinical models of pancreatic cancer. The study found that neutralizing specific immunosuppressive mechanisms dramatical...
Researchers developed predictive models using serum microRNAs to identify patients at risk of requiring early palliative care. The study used serum samples from 178 patients with various types of cancer and found that miRNA-based models had higher accuracy than clinical models in predicting referral to a palliative care unit.
The CodeBreaK 100 trial demonstrates meaningful anticancer activity with sotorasib in heavily pretreated patients with KRAS G12C-mutated metastatic pancreatic cancer. The results show an objective response rate of 21.1% and a median time-to-response of 1.5 months.
A new study has identified a potential therapy for metastatic colon cancer by targeting the molecule hyaluronan, which accumulates in tumors and shuts down immune cells that can kill tumor cells. The experimental therapy, hyaluronidase, shrinks tumors and allows immune cells to attack tumor cells.
The study reveals that SETD1A overexpression is associated with poorer disease-free survival in pancreatic cancer patients. Artificially cultured cells showed increased cell growth and migration when SETD1A levels were overexpressed, while knocking down SETD1A expression led to decreased RUVBL1 gene expression.
Scientists at UCSF have engineered T cells to produce a potent anti-cancer cytokine that only activates in tumor cells, eliminating melanoma and pancreatic cancer in mice. The treatment uses IL-2, which supercharges T cells to kill cancer cells while protecting against infection, offering a promising new strategy for fighting hard-to-t...
A new clinical trial has found that chemotherapy before surgery significantly improves 1-year survival rates for patients with borderline resectable pancreatic cancer. The study, led by the University of Liverpool, compared immediate surgery with short-course neoadjuvant therapy and found a significant survival benefit.
Researchers visualized the (pro)renin receptor's protein binding site and found hand-shaped grooves allowing for multiple protein binding. The study provides new insight into disease pathogenesis and aids in exploring novel treatments.
A nationwide retrospective study showed that adjuvant chemotherapy after neo-adjuvant chemotherapy and surgery significantly improved overall survival in patients with pancreatic adenocarcinoma, regardless of lymph node status or resection margins. The study included nearly 900 patients and was published in JAMA Oncology.
Researchers developed a small molecule inhibitor that successfully shrunk tumors or stopped cancer growth in preclinical models of pancreatic cancer. The drug, MRTX1133, not only targets cancer cells but also cooperates with the immune system to produce a durable response to treatment.
Researchers at VCU Massey Cancer Center discovered the inactivation of NF1 as a potential genetic driver for pancreatic cancer. The study suggests that targeting NF1 could create vulnerabilities for therapeutic advantage in mutant KRAS-bearing tumors.
Researchers at University of Pittsburgh have designed novel nanoparticles that co-deliver a chemotherapy drug and a novel immunotherapy, shrinking tumors in mouse models of colon and pancreatic cancer. The therapy silences a gene involved in immunosuppression by blocking Xkr8 protein distribution on the cell membrane.
A recent study found that MRI-guided adaptive radiation therapy, also known as SMART, has shown promising safety and patient outcomes data for treating locally advanced and borderline resectable pancreatic cancer. The study, led by Henry Ford Health, reported no incidence of acute grade 3 or higher gastrointestinal toxicity, with preli...
The ESMO Asia Congress 2022 will focus on the latest scientific and clinical advances in oncology, with a special emphasis on the Asia-Pacific region. Media representatives can register for coverage through the official media registration form.
A new study by Cedars-Sinai investigators has identified risk factors for developing diabetes in people with chronic pancreatitis, including smoking and being overweight. The findings suggest that models can be built to predict diabetes risk, allowing clinicians to connect patients with weight loss or smoking cessation programs.
Researchers found that a new drug inhibiting GRP78 effectively reduces SARS-CoV-2 replication in human lung cells. The drug also shows potential in treating certain types of cancer by suppressing mutant KRAS proteins.
A specialized triage algorithm, ROCA test, enables earlier stage diagnosis in women deferring preventive surgery, saving NHS costs. The approach results in fewer major surgical interventions and lower risk of wider disease spread.
In the ARROS-1 trial, 48% of patients achieved partial responses to NVL-520, with responses seen across all dose levels and in heavily pre-treated patients. The treatment also showed promise for brain metastases, with three out of three patients experiencing measurable response or no emergence of new metastases.
A Phase Ib clinical trial found that sequential administration of PARP inhibitor olaparib and WEE1 inhibitor adavosertib is safe and well-tolerated, with promising signs of anti-tumor activity in patients with advanced cancers driven by DNA damage response mutations. The combination showed durable responses in patients with resistant c...
Researchers have found a drug that targets the key, cancer-causing gene MYC has been able to inhibit its function safely and effectively. Eight out of 12 patients showed stabilisation of disease after treatment with OMO-103, with one patient experiencing a reduction in tumour-derived DNA circulating in the blood stream.
Researchers at Duke University have developed a novel treatment that combines internal radiation and chemotherapy to eliminate tumors in 80% of mice with pancreatic cancer. The approach uses a gel-like depot implanted with radioactive iodine-131, which deposits beta radiation directly into the tumor without affecting surrounding tissue.
Scientists at the University of Florida have identified two small molecules that inhibit precancerous cell progression and reverse a key process involved in pancreatic cancer progression. This discovery could lead to earlier treatments and improved survival rates for patients with pancreatic cancer.
Virginia Tech researchers found that a common oral bacterium, Fusobacterium nucleatum, drives pancreatic cancer cell proliferation and migration. The bacterium can infect normal pancreatic tissue cells, stimulating nearby cancer cells to grow and spread rapidly.
Researchers developed an antibody-based treatment that targets cadherins on circulating tumor cells, eliminating them in mouse models of breast and pancreatic cancer. The therapy shows promise in preventing cancer metastasis, a leading cause of cancer-related deaths.
Scientists at The Wistar Institute have discovered a correlation between mitochondrial dysfunction and aggressive pancreatic cancer. An 11-gene signature indicative of mitochondrial reprogramming in tumors has been identified, which correlates with poor patient outcomes and treatment resistance.
Researchers propose an optical imaging system for real-time hypoxia imaging in cancer treatment. The technique utilizes protoporphyrin IX to enhance contrast between tumors and healthy tissues, allowing for more effective surgical removal.
Researchers from Rutgers Cancer Institute have identified specific microorganisms associated with inflammation and poor survival in pancreatic tumors. These microbial signatures can be used as new targets for earlier diagnosis or treatment of the fourth leading cause of cancer death.